Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports.

ABSTRACT:

Introduction

Diabetic ketoacidosis (DKA) is one of the most serious acute complications of diabetes. Its defining features are hyperglycemia and ketoacidosis. Euglycemic DKA (EDKA) affects patients whose serum glucose levels are within the normal range. The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is one of the newly identified risks for this condition.

Case presentation

A 75-year-old woman with type 2 diabetes mellitus presented to our emergency department with decreased consciousness and decreased oral intake for two days. She had been diagnosed with a cerebrovascular accident for 12 days, and empagliflozin was added to her medications. Laboratory evaluation revealed metabolic acidosis, despite a minimally elevated serum glucose concentration. The patient w

SUBMITTER: Altowayan WM 

PROVIDER: S-EPMC9793230 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature